antibody

ErbB2, phosphorylated (Tyr1248) (Receptor Tyrosine-protein Kinase erbB-2, Metastatic Lymph Node Gene 19 Protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine Kinase-type Cell Surface Receptor HER2, CD340, p185erbB2, HER2, MLN19, NEU,

MBS625790

0.05 mg

390 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, immunohistochemistry, immunocytochemistry

Antibody

ErbB2, phosphorylated (Tyr1248) (Receptor Tyrosine-protein Kinase erbB-2, Metastatic Lymph Node Gene 19 Protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine Kinase-type Cell Surface Receptor HER2, CD340, p185erbB2, HER2, MLN19, NEU, NGL)

ErbB2

Anti -ErbB2, phosphorylated (Tyr1248) (Receptor Tyrosine-protein Kinase erbB-2, Metastatic Lymph Node Gene 19 Protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine Kinase-type Cell Surface Receptor HER2, CD340, p185erbB2, HER2, MLN19, NEU, NGL)

ERBB2; ERBB2; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 19 protein; tyrosine kinase-type cell surface receptor HER2; neuroblastoma/glioblastoma derived oncogene homolog; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)

ERBB2; ERBB2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu

Q9NP09_HUMAN

Polyclonal

IgG

Rabbit

Human, Mouse, Rat

Recognizes human ErbB2 when phosphorylated at tyrosine 1248. Species Crossreactivity: mouse, rat.

Affinity Purified. Purified by immunoaffinity chromatography.

Supplied as a liquid in PBS (without Mg2+ and Ca2+), pH 7.4, 150mM sodium chloride, 0.02% sodium azide, 50% glycerol.

1mg/ml

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

Suitable for use in Immunofluorescence, Western Blot, and Immunohistochemistry. Dilution: Immunofluorescence: 1:100-1:200. Western Blot: 1:500-1:1,000. Immunohistochemistry: 1:50-1:100

Immunogen: Synthetic phosphopeptide corresponding to human HER2 around the phosphorylation site of tyrosine1248 (P-E-YP-L-G).

Antibodies; Abs to Oncoproteins

The ErbB-2 proto-oncogene, also called Neu, EGFR-2 or HER-2, is a member of the transmembrane receptor tyrosine kinase family, which also includes EGF receptor and EGFR-3 (HER-3 or ErbB-3). Although, ErbB-2 does not have any known high-affinity ligands, its kinase activity can be activated without ligand by either overexpression or heteroassociation with other members of the ErbB family. Amplification of the ErbB-2 gene and overexpression of its product has been detected in almost 40% of primary human breast tumors, which correlates with poor prognosis in node positive breast cancer. ErbB-2 overexpression is also observed in ovarian, gastric, salivary and non-small cell lung carcinomas. Because of this, ErbB-2 is one of the major drug targets for breast cancer and other cancer treatments.

6857751

Q9NP09

4,204 Da

Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Alpha6-Beta4 Integrin Signaling Pathway (198807); Axon Guidance Pathway (105688); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459); Endometrial Cancer Pathway (83109); Endometrial Cancer Pathway (521)

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq]

HER2: a proto-oncogenic receptor tyrosine kinase of the EGFR family. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. Not activated by EGF, TGF- alpha and amphiregulin. Amplified in breast cancer. Overexpression induces constitutive activity, and the gene is amplified or overexpressed in up to 30% of breast cancers, correlating with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. One SNP shows predisposition to breast and gastric cancer. Inhibitors: Herceptin, lapatinib, PKI-166, EKB-569, CI-1033. Protein type: Protein kinase, TK; Kinase, protein; Oncoprotein; EC 2.7.10.1; Protein kinase, tyrosine (receptor); Membrane protein, integral; TK group; EGFR family. Chromosomal Location of Human Ortholog: 17q12. Cellular Component: basolateral plasma membrane; perinuclear region of cytoplasm; cytoplasm; apical plasma membrane; integral to membrane; plasma membrane; endosome membrane; cytoplasmic vesicle; nucleus; receptor complex. Molecular Function: protein dimerization activity; protein C-terminus binding; identical protein binding; receptor signaling protein tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; protein phosphatase binding; protein binding; transmembrane receptor activity; ErbB-3 class receptor binding; protein heterodimerization activity; protein-tyrosine kinase activity; growth factor binding; ATP binding. Biological Process: myelination; axon guidance; phosphoinositide 3-kinase cascade; peptidyl-tyrosine phosphorylation; positive regulation of cell adhesion; wound healing; positive regulation of translation; nerve growth factor receptor signaling pathway; protein amino acid autophosphorylation; heart development; motor axon guidance; signal transduction; enzyme linked receptor protein signaling pathway; protein amino acid phosphorylation; positive regulation of transcription from RNA polymerase I promoter; positive regulation of MAP kinase activity; cell surface receptor linked signal transduction; oligodendrocyte differentiation; neuromuscular junction development; epidermal growth factor receptor signaling pathway; negative regulation of immature T cell proliferation in the thymus; regulation of microtubule-based process; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; transcription, DNA-dependent; positive regulation of cell growth; regulation of angiogenesis; peripheral nervous system development; cell proliferation; positive regulation of transcription from RNA polymerase III promoter; innate immune response; positive regulation of protein amino acid phosphorylation; transmembrane receptor protein tyrosine kinase signaling pathway; positive regulation of epithelial cell proliferation. Disease: Gastric Cancer; Lung Cancer; Glioma Susceptibility 1

0.05 mg

390 USD